Sickle Cell Disease | CHOP Research Institute
 

Sickle Cell Disease

Published on
Mar 15, 2024
This week, CHOP announces two new Frontier Programs, and researchers define the origins of hematopoietic failure in Fanconi anemia.
Published on
Jan 3, 2024
After decades of limited progress in treating sickle cell disease, we have reached an historical moment with two new gene therapies.
Published on
Dec 27, 2023
Kemar Prussien, PhD, participates in a program that prepares diverse postdocs and early-stage scientists to become tenure track faculty.
Published on
Dec 22, 2023
Our research news roundup highlights newly approved gene therapies, insights into common genetic epilepsy disorders, and head injury prevention for young athletes.
Published on
Dec 8, 2023
Our research news roundup highlights the improvements made in CAR therapies through structural biology discoveries and cost reduction strategies.
Published on
Jun 28, 2023
Kandace Gollomp, MD, attending physician in the Division of Hematology, studies neutrophils to understand how they interact with infections.
Published on
Sep 30, 2022
Learn about novel findings and new grants from Children’s Hospital of Philadelphia researchers.

Dr. Thompson is the chief of the Division of Hematology at CHOP and holds the Elias Schwartz, MD, Endowed Chair in Hematology. Her research focuses on sickle cell disease and thalassemia.

E-mail:
thompsona7 [at] chop.edu
Published on
Jun 24, 2022
This week’s In the News features endocrinology research, news on gene therapy in blood disorders, CAR T-cell therapy, and more.

This Phase 2 clinical research study is evaluating the safety and effectiveness of a once-daily oral investigational medicine that may improve anemia and reduce the need for red blood cell (RBC) transfusions among some patients who are chronically transfused.